In conclusion, afatinib is a viable treatment option for tissue or ctDNA-detected EGFR mutant NSCLC patients considered unsuitable for chemotherapy because of comorbidities, with a proportion of patients achieving long-term clinical benefit, although osimertinib may be an alternative option in the modern era. Here, EGFR is linked to non-small cell lung carcinoma.